Long-term follow-up at 10-years of patients enrolled in the fingolimod Phase II program in relapsing multiple sclerosis

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-002660-17

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To investigate whether continuous use of fingolimod over 10 years reduces the progression of disability, as measured by the mean Expanded Disability Status Scale (EDSS) score, compared to shorter treatment duration


Critère d'inclusion

  • Multiple sclerosis